MolecuLight Announces Integration with Intellicure Electronic Health Record (EHR) for Seamless Data and Image Transfer USA - English USA - Deutsch USA - English
The PennZone/10280156

Trending...
PITTSBURGH, Aug. 27, 2024 ~ MolecuLight Corp., a renowned company in the field of fluorescence imaging technology, has recently announced a major development in their flagship wound imaging device, MolecuLightDX. The company has successfully integrated this device with the Intellicure EHR platform, a leading electronic health record system.

This integration allows wound care clinicians who use Intellicure's SMART apps or its complete EHR solution to seamlessly upload standard and fluorescence images and measurements captured with the MolecuLight device at the point-of-care directly to the patient's record. This not only optimizes their workflow but also enables them to digitally document their patients' wounds.

The benefits of this integration are numerous, including direct (Wi-fi enabled) EHR-to-device transfer of patient data, automatic upload of images from device-to-EHR, digital wound measurement and standard wound images, as well as bacterial autofluorescence images that indicate the presence and location of harmful bacteria and biofilm in and around wounds. Additionally, this integration is scalable and supports the use of several DX devices per site.

More on The PennZone
Anil Amlani, CEO of MolecuLight Inc., expressed his excitement about this development by stating that "optimizing our customers' clinical workflow is a top priority here at MolecuLight." He further added that "we are proud to announce the inclusion of our MolecuLight platform in Intellicure EHR." Amlani also highlighted the advanced features of MolecuLightDX, which is an extensively validated FDA-cleared Class II device that integrates three essential functions: detection of harmful bacteria linked to infection, digital wound measurement, and aid to clinicians in treatment planning. He also mentioned that an extensive body of peer-reviewed publications demonstrates faster healing rates, better resource allocation, cost savings, and improved patient engagement with the use of their advanced imaging platform.

Dr. Caroline Fife, Chief Medical Officer at Intellicure, also expressed her enthusiasm about this integration by stating that "Intellicure's seamless wound care charting platform is a perfect match with MolecuLight." She further added that "Intellicure is the only wound care EHR that provides relevant point-of-care clinical practice suggestions." Dr. Fife also highlighted the importance of this integration in optimizing patient care and improving wound outcomes.

More on The PennZone
The MolecuLight i:X and DX are the only Class ll FDA-cleared, CE-Marked, and Health Canada approved imaging devices available in the market for the real-time detection of elevated bacterial burden in and around wounds. With a robust body of clinical evidence, these devices are used globally by leading wound care facilities.

On the other hand, Intellicure is a wound care software used by America's advanced wound centers. Wound clinicians using Intellicure's SMART apps for Cerner and Epic, wound care mobile apps, and/or Intellicure's complete EHR solution enjoy clean clinical workflow, proven regulatory compliance, unparalleled reimbursement rates, and are recognized by CMS as leaders in quality patient care. This integration with MolecuLight further strengthens their position as a leader in the field of wound care.

Overall, this integration between MolecuLightDX and Intellicure EHR is a significant development that will greatly benefit both clinicians and patients. It not only streamlines their workflow but also provides valuable information about harmful bacteria to aid in treatment planning and ultimately improve patient outcomes.
Filed Under: Business
Show All News | Report Violation

0 Comments

Latest on The PennZone